The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma

Geoffrey L. Uy; Michael H. Tomasson; Alisa Ruddell; John F. DiPersio; Ravi Vij

The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma

Geoffrey L. Uy
, Michael H. Tomasson
, Alisa Ruddell
, John F. DiPersio
, Ravi Vij

Research output: Contribution to journal › Article › peer-review

Abstract

Eight patients with refractory multiple myeloma were treated with clofarabine 4 mg/m²/day on days 1-5 of a 28 day cycle. No objective evidence of antimyeloma activity was observed (median time to progression of 52 days). All patients experienced grade 3-4 neutropenia and a greater than 50% decrease in platelet counts during treatment.

Original language	English
Pages (from-to)	1581-1582
Number of pages	2
Journal	Haematologica
Volume	91
Issue number	11
State	Published - Nov 1 2006

Keywords

Clinical trial
Clofarabine
Multiple myeloma

Cite this

@article{a5b944122f384fb3a6a128c23be9f13a,

title = "The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma",

abstract = "Eight patients with refractory multiple myeloma were treated with clofarabine 4 mg/m2/day on days 1-5 of a 28 day cycle. No objective evidence of antimyeloma activity was observed (median time to progression of 52 days). All patients experienced grade 3-4 neutropenia and a greater than 50\% decrease in platelet counts during treatment.",

keywords = "Clinical trial, Clofarabine, Multiple myeloma",

author = "Uy, \{Geoffrey L.\} and Tomasson, \{Michael H.\} and Alisa Ruddell and DiPersio, \{John F.\} and Ravi Vij",

year = "2006",

month = nov,

day = "1",

language = "English",

volume = "91",

pages = "1581--1582",

journal = "Haematologica",

issn = "0390-6078",

number = "11",

}

TY - JOUR

T1 - The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma

AU - Uy, Geoffrey L.

AU - Tomasson, Michael H.

AU - Ruddell, Alisa

AU - DiPersio, John F.

AU - Vij, Ravi

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Eight patients with refractory multiple myeloma were treated with clofarabine 4 mg/m2/day on days 1-5 of a 28 day cycle. No objective evidence of antimyeloma activity was observed (median time to progression of 52 days). All patients experienced grade 3-4 neutropenia and a greater than 50% decrease in platelet counts during treatment.

AB - Eight patients with refractory multiple myeloma were treated with clofarabine 4 mg/m2/day on days 1-5 of a 28 day cycle. No objective evidence of antimyeloma activity was observed (median time to progression of 52 days). All patients experienced grade 3-4 neutropenia and a greater than 50% decrease in platelet counts during treatment.

KW - Clinical trial

KW - Clofarabine

KW - Multiple myeloma

UR - https://www.scopus.com/pages/publications/33750963443

M3 - Article

C2 - 17043015

AN - SCOPUS:33750963443

SN - 0390-6078

VL - 91

SP - 1581

EP - 1582

JO - Haematologica

JF - Haematologica

IS - 11

ER -

The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma

Abstract

Keywords

Other files and links

Fingerprint

Cite this